Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics. The ...
London–listed PRTech firm Pathos Communications has developed proprietary AI platform PathosMind. For exclusive use by Pathos employees and partners, it surfaces stories that truly resonate with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results